What is the recommended dose, duration, and renal dosing adjustments for rebamipide in treating gastritis, gastric ulcer, or NSAID‑induced ulcer disease, and what alternatives are available if the thrice‑daily regimen is not tolerated?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Rebamipide Dosing and Management

Rebamipide 100 mg three times daily for 8 weeks is the standard regimen for gastritis and gastric ulcers, with a newer twice-daily 150 mg formulation (AD-203) demonstrating non-inferior efficacy and potentially improved compliance. 1

Standard Dosing Regimen

  • Dose: 100 mg three times daily 1, 2, 3
  • Duration: 8 weeks for gastric ulcers and erosive gastritis 2, 3
  • Timing: Administered with meals to optimize mucosal protection 4

The traditional thrice-daily regimen has demonstrated significant efficacy across multiple clinical scenarios, including H. pylori-positive ulcers, NSAID-induced ulcers, and idiopathic gastric ulcers. 2

Alternative Dosing for Improved Compliance

If the thrice-daily regimen is not tolerated or compliance is a concern, rebamipide 150 mg twice daily (AD-203 formulation) is an effective alternative. 1

  • The twice-daily 150 mg formulation showed erosion improvement rates of 39.7% versus 43.8% for the standard thrice-daily 100 mg regimen, meeting non-inferiority criteria (95% CI: -13.09% to 5.06%). 1
  • Adverse event rates were similar between formulations (24 patients with AD-203 vs. 20 with standard rebamipide). 1
  • The simplified dosing schedule addresses the compliance concerns inherent in thrice-daily regimens, which is particularly relevant given that poor compliance increases NSAID-induced GI adverse events 4-6 fold. 5

Renal Dosing Adjustments

No specific renal dose adjustments for rebamipide are documented in the available literature. 4 The drug undergoes hepatic metabolism and renal excretion, but unlike many gastroprotective agents, formal renal dosing guidelines have not been established in clinical trials. 4

Clinical Context: Rebamipide vs. Guideline-Recommended Agents

While rebamipide demonstrates excellent efficacy for gastric ulcers, PPIs remain the guideline-recommended first-line agents for NSAID-induced ulcer prevention and treatment in Western practice. 6

Important Caveats:

  • PPIs are the preferred agents for therapy and prophylaxis of NSAID- and aspirin-associated GI injury according to ACCF/ACG/AHA consensus guidelines. 6
  • Standard-dose H2-receptor antagonists are inadequate for preventing NSAID-related gastric ulcers. 6
  • Misoprostol (600-800 mg/day) is FDA-approved for NSAID ulcer prevention but has a 20% discontinuation rate due to diarrhea and abdominal cramping. 6

Rebamipide's Specific Advantages:

  • Superior efficacy in NSAID-induced ulcers: Rebamipide showed complete healing in most patients with NSAID-related ulcers and significant improvement in gastric inflammation scores (2.38 vs. 1.75, p=0.011). 2
  • Adjunctive role in H. pylori eradication: When added to 1-week eradication therapy, rebamipide achieved 80.0% healing rates versus 66.1% with placebo (95% CI: 3.1-24.7; p=0.013). 3
  • Efficacy in PPI-refractory dyspepsia: In patients with chronic gastritis unresponsive to PPIs, rebamipide 300 mg daily for 8 weeks significantly improved symptoms, endoscopic mucosal injury scores, and histologic inflammation. 7
  • Excellent safety profile: Minimal adverse effects with widespread adoption across Southeast Asia and Russia. 8

Practical Algorithm for Use

  1. For NSAID-induced gastric ulcers: Consider rebamipide 100 mg three times daily for 8 weeks, particularly if PPIs have been inadequate or in Asian populations where rebamipide is more established. 2, 8

  2. For compliance concerns: Switch to rebamipide 150 mg twice daily formulation. 1

  3. For H. pylori-positive ulcers: Use rebamipide as adjunctive therapy following standard eradication regimens to enhance healing rates. 3

  4. For PPI-refractory gastritis: Trial rebamipide 300 mg daily (100 mg three times daily) for 8 weeks. 7

  5. In Western practice: Recognize that while rebamipide shows excellent efficacy, PPIs remain guideline-recommended first-line therapy; rebamipide may serve as an alternative or adjunctive agent. 6, 8

Common Pitfalls

  • Do not assume rebamipide replaces H. pylori eradication: Even with rebamipide, H. pylori eradication is essential in infected patients with ulcer history. 5
  • Avoid monotherapy in high-risk patients: For patients with prior ulcer complications on NSAIDs, gastroprotection with PPIs or rebamipide does not eliminate risk entirely. 5
  • Monitor compliance: The thrice-daily regimen may lead to poor adherence; consider the twice-daily formulation proactively. 5, 1

References

2
Research

Effect of rebamipide on gastric ulcer healing caused by Helicobacter pylori and/or NSAIDs or non NSAIDs-non H. pylori.

Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2009

8
Research

Rebamipide in gastric mucosal protection and healing: An Asian perspective.

World journal of gastrointestinal pharmacology and therapeutics, 2025

Related Questions

What is the recommended dosing regimen for ribamipide in adults with gastritis or peptic ulcer disease?
What are the indications, dosing regimen, administration instructions, contraindications, side effects, and alternative therapies for rebamipide in adults with gastritis, gastric ulcer, or NSAID‑induced gastric injury?
What times should Mucosta (rebamipide) and Normix (rifaximin) be given three times daily to keep them at least 30 minutes apart?
What are the contraindications for rebamipide, including hypersensitivity reactions and use during breastfeeding?
How do Mucopro (rebamipide) and Mucosta (rebamipide) differ in dosing schedule, efficacy, and patient adherence considerations?
For a patient on lamotrigine, including those with an MTHFR polymorphism, should folic acid be replaced with L‑methylfolate or folinic acid, or is standard folic acid supplementation appropriate?
Are fetal hiccups in the third trimester a normal finding that requires any treatment?
Should an elderly patient with gallstones continue ursodiol (ursodeoxycholic acid) twice daily indefinitely?
What are the acute and chronic health risks associated with methamphetamine use?
In which clinical scenarios should nebivolol be preferred over bisoprolol, and vice versa?
Can I prescribe azithromycin 500 mg once daily for three days for an adult with uncomplicated tonsillitis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.